What Is the Role of Palmitoylethanolamide Co-Ultramicronized with Luteolin on the Symptomatology Reported by Patients Suffering from Long COVID? A Retrospective Analysis Performed by a Group of General Practitioners in a Real-Life Setting
Observational studyHumansWith luteolin
This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Observational study
- Subjects
- Patients of nine general practitioners in the Rome area with symptoms after COVID-19; the number is not in the abstract
- Dose used in the study
- Co-ultramicronised palmitoylethanolamide with luteolin; dose not in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Patient-reported symptoms: pain, anxiety and depression, fatigue, brain fog, loss of smell and taste, overall health status
What the authors reported
The authors report that all patient-reported symptoms improved with supplementation, especially pain, mood, fatigue, brain fog and smell and taste.
Limits of this study
Retrospective, no control group, no blinding, and the abstract gives no patient numbers, no dose, no duration and no effect sizes. Symptoms after COVID-19 improve with time in most people. The authors themselves call the results preliminary. The senior authors have long-standing links with Epitech, which makes the product.
Source
PubMed 37686733 · doi:10.3390/nu15173701
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.